{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:06:27Z","timestamp":1771005987826,"version":"3.50.1"},"reference-count":65,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2020,7,31]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Different approaches have been investigated to develop a preventive or therapeutic\nvaccine, although none of them has been fully practical. Therapeutic vaccines against HIV-1\nhave been studied with the aim of eliminating the virus from reservoir cells with or without HAART\n(Highly Active Antiretroviral Therapy). Fusion proteins with the most immunogenic features among\nconserved regions can facilitate this achievement in such a variable virus. To achieve the most immunogenic\nand also conserved regions, bioinformatics tools are widely used to predict antigens\u2019 features\nbefore applying them.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed at the in vitro evaluation of p24 -Nef fusion protein based on the previous\nin silico design to achieve a potential therapeutic subunit vaccine against HIV-1.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> The truncated form of p24-Nef using AAY flexible linker and the full protein were expressed\nand evaluated in the prokaryotic system and confirmed by western blotting. We also used\npcDNA3.1 to transfect Lenti-X 293T cells. Moreover, lentiviral vectors were applied to produce recombinant\nvirions harboring the genes of interest and cell transduction.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Both fusion proteins in a truncated and a full form were expressed and confirmed by Anti Nef\npolyclonal antibody in western blotting. Recombinant virions were generated and transduced Lenti-X\n293T cells confirming by immunofluorescence microscope and p24 ELISA assay kit. Transduced cells\nwere analyzed by SDS-PAGE and western blotting, which resulted in approved protein expression.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Fusion protein of p24 and Nef is well expressed in eukaryotic cell lines according to its\npre-evaluated features by bioinformatics tools.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201817666200317121728","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T14:24:41Z","timestamp":1584455081000},"page":"387-395","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate Vaccines in Three Vehicles"],"prefix":"10.2174","volume":"17","author":[{"given":"Mona Sadat","family":"Larijani","sequence":"first","affiliation":[{"name":"Department of Hepatitis, AIDS and Blood Borne Diseases, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hassan","family":"Pouriayevali","sequence":"additional","affiliation":[{"name":"Department of Arboviruses and Viral Hemorrhagic Fevers (National Ref Lab), Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-179X","authenticated-orcid":true,"given":"Seyed Mehdi","family":"Sadat","sequence":"additional","affiliation":[{"name":"Department of Hepatitis, AIDS and Blood Borne Diseases, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitis","family":"Ramezani","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.copbio.2016.03.007","volume":"42","author":"Koff,W.C","year":"2016","unstructured":"Koff.; W.C. A shot at AIDS. Curr. Opin. Biotechnol. 2016,42,147-151. http:\/\/dx.doi.org\/10.1016\/j.copbio.2016.03.007 PMID: 27153215","journal-title":"Curr.Opin.Biotechnol"},{"key":"ref=2","author":"HIV\/AIDS","unstructured":"HIV\/AIDS. UNAIDS. 2017","journal-title":"2017"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367(5)","author":"Baeten, J.M.","year":"2012","unstructured":"Baeten, J.M.; Donnell,D.; Ndase,P.; Mugo, N.R.; Campbell, J.D.; Wangisi,J.; Tappero, J.W.; Bukusi, E.A.; Cohen, C.R.; Katabira,E.; Ronald,A.; Tumwesigye,E.; Were,E.; Fife, K.H.; Kiarie,J.; Farqu-har,C.; John-Stewart,G.; Kakia,A.; Odoyo,J.; Mucunguzi,A.; Nakku-Joloba,E.; Twesigye,R.; Ngure,K.; Apaka,C.; Tamooh,H.; Gabona,F.; Mujugira,A.; Panteleeff,D.; Thomas, K.K.; Kidoguchi,L.; Krows,M.; Revall,J.; Morrison,S.; Haugen,H.; Emmanuel-Ogier,M.; Ondrejcek,L.; Coombs, R.W.; Frenkel,L.; Hendrix,C.; Bumpus, N.N.; Bangsberg,D.; Haberer, J.E.; Stevens, W.S.; Lingappa, J.R.; Ce-lum,C.; Partners Pr, E.P.S.T. Partners PrEP study team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women, N. Engl, J. Med. 2012,367(5),399-410. http:\/\/dx.doi.org\/10.1056\/NEJMoa1108524 PMID: 22784037","journal-title":"N.Engl, J.Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7774\/cevr.2016.5.1.6","volume":"5(1)","author":"Shin,S.Y","year":"2016","unstructured":"Shin.; S.Y. Recent update in HIV vaccine development. Clin. Exp. Vaccine Res. 2016,5(1),6-11. http:\/\/dx.doi.org\/10.7774\/cevr.2016.5.1.6 PMID: 26866018","journal-title":"Clin.Exp.Vaccine Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.coviro.2018.02.004","volume":"29","author":"Rios,A","year":"2018","unstructured":"Rios.; A. Fundamental challenges to the development of a preventive HIV vaccine. Curr. Opin. Virol. 2018,29,26-32. http:\/\/dx.doi.org\/10.1016\/j.coviro.2018.02.004 PMID: 29549802","journal-title":"Curr.Opin.Virol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.coviro.2016.02.010","volume":"17","author":"Gray, G.E.","year":"2016","unstructured":"Gray, G.E.; Laher,F.; Lazarus,E.; Ensoli,B.; Corey, L. Approaches to preventative and therapeutic HIV vaccines. Curr. Opin. Virol. 2016,17,104-109. http:\/\/dx.doi.org\/10.1016\/j.coviro.2016.02.010 PMID: 26985884","journal-title":"Curr.Opin.Virol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/14760584.2019.1557521","volume":"18(1)","author":"Rahman, M.A.","year":"2019","unstructured":"Rahman, M.A.; Robert-Guroff, M. Accelerating HIV vaccine devel-opment using non-human primate models. Expert Rev. Vaccines. 2019,18(1),61-73. http:\/\/dx.doi.org\/10.1080\/14760584.2019.1557521 PMID: 30526159","journal-title":"Expert Rev.Vaccines"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4172\/2155-6113.1000359","volume":"5","author":"Barry,M.S","year":"2014","unstructured":"Barry.; M.S. Trial, error, and breakthrough: a review of HIV vaccine development, J. AIDS Clin. Res. 2014,5,11. http:\/\/dx.doi.org\/10.4172\/2155-6113.1000359","journal-title":"AIDS Clin.Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nm1461","volume":"13(1)","author":"Fischer,W.","year":"2007","unstructured":"Fischer,W.; Perkins,S.; Theiler,J.; Bhattacharya,T.; Yusim,K.; Funkhouser,R.; Kuiken,C.; Haynes,B.; Letvin, N.L.; Walker, B.D.; Hahn, B.H.; Korber, B.T. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 2007,13(1),100-106. http:\/\/dx.doi.org\/10.1038\/nm1461 PMID: 17187074","journal-title":"Nat.Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14712598.2017.1282457","volume":"17(3)","author":"Cohen, K.W.","year":"2017","unstructured":"Cohen, K.W.; Frahm, N. Current views on the potential for develop-ment of a HIV vaccine. Expert Opin. Biol. Ther. 2017,17(3),295-303. http:\/\/dx.doi.org\/10.1080\/14712598.2017.1282457 PMID: 28095712","journal-title":"Expert Opin.Biol.Ther"},{"key":"ref=11","author":"Milani,A.","unstructured":"Milani,A.; Bolhassani,A.; Shahbazi,S.; Motevalli,F.; Sadat, SM.; Soleymani, S Small heat shock protein. 27: an effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity. Immunol. Let.t. 2017,191,16-22","journal-title":"Immunol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"013","DOI":"10.29328\/journal.aaai.1001013","volume":"2(1)","author":"Mona,Sadat,L.;","year":"2018","unstructured":"Mona Sadat,L.; Seyed Mehdi,S.; Amitis, R. HIV-1 Immune evasion: the main obstacle toward a successful vaccine. Archiv. Asthma, Al-lergy Immunol. 2018,2(1),013-015","journal-title":"Archiv..Asthma, Al-lergy Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/21645515.2016.1276138","volume":"13(5)","author":"Hsu, D.C.","year":"2017","unstructured":"Hsu, D.C.; O\u2019Connell, R.J. Progress in HIV vaccine development. Hum. Vaccin. Immunother. 2017,13(5),1018-1030. http:\/\/dx.doi.org\/10.1080\/21645515.2016.1276138 PMID: 28281871","journal-title":"Hum.Vaccin.Immunother"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12859-016-0918-8","volume":"17","author":"Shamriz,S.","year":"2016","unstructured":"Shamriz,S.; Ofoghi, H. Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant. BMC Bioinformat. 2016,17,71. http:\/\/dx.doi.org\/10.1186\/s12859-016-0918-8 PMID: 26851942","journal-title":"BMC Bioinformat"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e94240","DOI":"10.1371\/journal.pone.0094240","volume":"9(4)","author":"Liu,Y.","year":"2014","unstructured":"Liu,Y.; Rao,U.; McClure,J.; Konopa,P.; Manocheewa,S.; Kim,M.; Chen,L.; Troyer, R.M.; Tebit, D.M.; Holte,S.; Arts, E.J.; Mullins, J.I. Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different ge-netic backgrounds. PLoS One. 2014,9(4),e94240. http:\/\/dx.doi.org\/10.1371\/journal.pone.0094240 PMID: 24713822","journal-title":"PLoS One"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12981-017-0176-5","volume":"14(1)","author":"Kang, C.Y.","year":"2017","unstructured":"Kang, C.Y.; Gao, Y. Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines. AIDS Res. Ther. 2017,14(1),47. http:\/\/dx.doi.org\/10.1186\/s12981-017-0176-5 PMID: 28893272","journal-title":"AIDS Res.Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biomaterials.2017.05.001","volume":"136","author":"Courant,T.","year":"2017","unstructured":"Courant,T.; Bayon,E.; Reynaud-Dougier, H.L.; V illiers,C.; Men-neteau,M.; Marche, P.N.; Navarro, F.P. Tailoring nanostructured lipid carriers for the delivery of protein antigens: Physicochemical proper-ties versus immunogenicity studies. Biomaterials. 2017,136,29-42. http:\/\/dx.doi.org\/10.1016\/j.biomaterials.2017.05.001 PMID: 28511142","journal-title":"Biomaterials"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ni.2264","volume":"13(5)","author":"McMichael, A.J.","year":"2012","unstructured":"McMichael, A.J.; Haynes, B.F. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 2012,13(5),423-427. http:\/\/dx.doi.org\/10.1038\/ni.2264 PMID: 22513323","journal-title":"Nat.Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1570162X17666190618160608","volume":"17(2)","author":"Larijani, M.S.","year":"2019","unstructured":"Larijani, M.S.; Ramezani,A.; Sadat, S.M. Updated studies on the development of HIV therapeutic vaccine. Curr. HIV Res. 2019,17(2),75-84. http:\/\/dx.doi.org\/10.2174\/1570162X17666190618160608 PMID: 31210114","journal-title":"Curr.HIV Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"7049","DOI":"10.1128\/JVI.00327-09","volume":"83(14)","author":"Steers, N.J.","year":"2009","unstructured":"Steers, N.J.; Peachman, K.K.; McClain, S.R.; Alving, C.R.; Rao, M. Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affects antigen presentation, J. Virol. 2009,83(14),7049-7061. http:\/\/dx.doi.org\/10.1128\/JVI.00327-09 PMID: 19403671","journal-title":"Virol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.imlet.2015.05.010","volume":"166(1)","author":"Krupka,M.","year":"2015","unstructured":"Krupka,M.; Zachova,K.; Cahlikova,R.; Vrbkova,J.; Novak,Z.; Sebela,M.; Weigl,E.; Raska, M. Endotoxin-minimized HIV-1 p24 fused to murine HSP70 activates dendritic cells, facilitates endocytosis and p24-specific Th1 response in mice. Immunol. Lett. 2015,166(1),36-44. http:\/\/dx.doi.org\/10.1016\/j.imlet.2015.05.010 PMID: 26021827","journal-title":"Immunol.Lett"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/QAI.0000000000000852","volume":"71(3)","author":"Gandhi, R.T.","year":"2016","unstructured":"Gandhi, R.T.; Kwon, D.S.; Macklin, E.A.; Shopis, J.R.; McLean, A.P.; McBrine,N.; Flynn,T.; Peter,L.; Sbrolla,A.; Kaufmann, D.E.; Porichis,F.; Walker, B.D.; Bhardwaj,N.; Barouch, D.H.; Kavanagh, D.G. Immunization of HIV-1-infected persons with autologous den-dritic cells transfected with mRNA encoding HIV-1 Gag and Nef: re-sults of a randomized, placebo-controlled clinical trial, J. Acquired Immune Deficien. Syndromes. 2016,71(3),246-53","journal-title":"Acquired Immune Deficien..Syndromes"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/eji.201545465","volume":"46(3)","author":"Salabert,N.","year":"2016","unstructured":"Salabert,N.; Todorova,B.; Martinon,F.; Boisgard,R.; Zurawski,G.; Zurawski,S.; Dereuddre-Bosquet,N.; Cosma,A.; Kortulewski,T.; Banchereau,J.; Levy,Y.; Le Grand,R.; Chapon, C. Intradermal injec-tion of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. Eur, J. Immunol. 2016,46(3),689-700. http:\/\/dx.doi.org\/10.1002\/eji.201545465 PMID: 26678013","journal-title":"Eur, J.Immunol"},{"key":"ref=24","author":"Epaulard,O.","unstructured":"Epaulard,O.; Adam,L.; Poux,C.; Zurawski,G.; Salabert,N.; Rosen-baum,P.; Dereuddre-Bosquet,N.; Zurawski,S.; Flamar, A.L.; Oh,S.; Romain,G.; Chapon,C.; Banchereau,J.; Levy,Y.; Le Grand,R.; Mar-tinon, F. Macrophage-and neutrophil-derived TNF-alpha instructs skin langerhans cells to prime antiviral immune responses, J. Immunol. (Baltimore, Md. : 1950),2014,193(5),2416-26","journal-title":"Immunol.(Baltimore, Md..: 1950)"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2006.02.006","volume":"112(2)","author":"Ataman-Onal,Y.","year":"2006","unstructured":"Ataman-Onal,Y.; Munier,S.; Ganee,A.; Terrat,C.; Durand, P.Y.; Battail,N.; Martinon,F.; Le Grand,R.; Charles, M.H.; Delair,T.; Verrier, B. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune re-sponses in various animal models, J. control. Release Soc. 2006,112(2),175-85","journal-title":"control..Release Soc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e111085","DOI":"10.1371\/journal.pone.0111085","volume":"9(10)","author":"Kulkarni,V.","year":"2014","unstructured":"Kulkarni,V.; Valentin,A.; Rosati,M.; Rolland,M.; Mullins, J.I.; Pavlakis, G.N.; Felber, B.K. HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recog-nition in macaques. PLoS One. 2014,9(10),e111085. http:\/\/dx.doi.org\/10.1371\/journal.pone.0111085 PMID: 25338098","journal-title":"PLoS One"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e1424","DOI":"10.1371\/journal.pone.0001424","volume":"3(1)","author":"Rolland,M.","year":"2008","unstructured":"Rolland,M.; Heckerman,D.; Deng,W.; Rousseau, C.M.; Coovadia,H.; Bishop,K.; Goulder, P.J.; Walker, B.D.; Brander,C.; Mu-llins, J.I. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One. 2008,3(1),e1424. http:\/\/dx.doi.org\/10.1371\/journal.pone.0001424 PMID: 18183304","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nm1520","volume":"13(1)","author":"Kiepiela,P.","year":"2007","unstructured":"Kiepiela,P.; Ngumbela,K.; Thobakgale,C.; Ramduth,D.; Honey-borne,I.; Moodley,E.; Reddy,S.; de Pierres,C.; Mncube,Z.; Mkhwa-nazi,N.; Bishop,K.; van der Stok,M.; Nair,K.; Khan,N.; Crawford,H.; Payne,R.; Leslie,A.; Prado,J.; Prendergast,A.; Frater,J.; McCarthy,N.; Brander,C.; Learn, G.H.; Nickle,D.; Rousseau,C.; Coovadia,H.; Mullins, J.I.; Heckerman,D.; Walker, B.D.; Goulder, P. CD8+ T-cell responses to different HIV proteins have discordant asso-ciations with viral load. Nat. Med. 2007,13(1),46-53. http:\/\/dx.doi.org\/10.1038\/nm1520 PMID: 17173051","journal-title":"Nat.Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1128\/JVI.80.6.3122-3125.2006","volume":"80(6)","author":"Zu\u00f1iga,R.","year":"2006","unstructured":"Zu\u00f1iga,R.; Lucchetti,A.; Galvan,P.; Sanchez,S.; Sanchez,C.; Her-nandez,A.; Sanchez,H.; Frahm,N.; Linde, C.H.; Hewitt, H.S.; Hilde-brand,W.; Altfeld,M.; Allen, T.M.; Walker, B.D.; Korber, B.T.; Leit-ner,T.; Sanchez,J.; Brander, C. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunode-ficiency virus control, J. Virol. 2006,80(6),3122-3125. http:\/\/dx.doi.org\/10.1128\/JVI.80.6.3122-3125.2006 PMID: 16501126","journal-title":"Virol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41541-018-0086-0","volume":"3","author":"Bayon,E.","year":"2018","unstructured":"Bayon,E.; Morlieras,J.; Dereuddre-Bosquet,N.; Gonon,A.; Gosse,L.; Courant,T.; Le Grand,R.; Marche, P.N.; Navarro, F.P. Overcom-ing immunogenicity issues of HIV p24 antigen by the use of innova-tive nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates. NPJ Vaccines. 2018,3,46-46. http:\/\/dx.doi.org\/10.1038\/s41541-018-0086-0","journal-title":"NPJ Vaccines"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1128\/JVI.03230-13","volume":"88(5)","author":"Veillette,M.","year":"2014","unstructured":"Veillette,M.; D\u00e9sor meaux,A.; Medjahed,H.; Gharsallah, N.E.; Coutu,M.; Baalwa,J.; Guan,Y.; Lewis,G.; Ferrari,G.; Hahn, B.H.; Haynes, B.F.; Robinson, J.E.; Kaufmann, D.E.; Bonsignori,M.; So-droski,J.; Finzi, A. Interaction with cellular CD4 exposes HIV-1 enve-lope epitopes targeted by antibody-dependent cell-mediated cytotoxic-ity, J. Virol. 2014,88(5),2633-2644. http:\/\/dx.doi.org\/10.1128\/JVI.03230-13 PMID: 24352444","journal-title":"Virol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.bbagen.2015.01.003","volume":"1850(4)","author":"Pawlak, E.N.","year":"2015","unstructured":"Pawlak, E.N.; Dikeakos, J.D. HIV-1 Nef: a master manipulator of the membrane trafficking machinery mediating immune evasion. Biochim. Biophys. Acta. 2015,1850(4),733-741. http:\/\/dx.doi.org\/10.1016\/j.bbagen.2015.01.003 PMID: 25585010","journal-title":"Biochim.Biophys.Acta"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1128\/JVI.02725-06","volume":"81(8)","author":"Chaudhuri,R.","year":"2007","unstructured":"Chaudhuri,R.; Lindwasser, O.W.; Smith, W.J.; Hurley, J.H.; Bonifac-ino, J.S. Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor, J. Virol. 2007,81(8),3877-3890. http:\/\/dx.doi.org\/10.1128\/JVI.02725-06 PMID: 17267500","journal-title":"Virol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12981-017-0175-6","volume":"14(1)","author":"Dekaban, G.A.","year":"2017","unstructured":"Dekaban, G.A.; Dikeakos, J.D. HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure. AIDS Res. Ther. 2017,14(1),53. http:\/\/dx.doi.org\/10.1186\/s12981-017-0175-6 PMID: 28893294","journal-title":"AIDS Res.Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1097\/ QAD.0000000000001202","volume":"30(16)","author":"Park, S.Y.","year":"2016","unstructured":"Park, S.Y.; Mack, W.J.; Lee, H.Y. Enhancement of viral escape in HIV-1 Nef by STEP vaccination. AIDS. 2016,30(16),2449-2458. http:\/\/dx.doi.org\/10.1097\/ QAD.0000000000001202 PMID: 27427874","journal-title":"AIDS"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases6020042","volume":"6(2)","author":"Lundstrom,K","year":"2018","unstructured":"Lundstrom.; K. Viral vectors in gene therapy. Diseases. 2018,6(2),42. http:\/\/dx.doi.org\/10.3390\/diseases6020042 PMID: 29883422","journal-title":"Diseases"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2174\/157016211795945223","volume":"9(3)","author":"Sadat, S.M.","year":"2011","unstructured":"Sadat, S.M.; Zabihollahi,R.; Aghasadeghi, M.R.; Vahabpour,R.; Siadat, S.D.; Memarnejadian,A.; Azadmanesh,K.; Parivar, K. Appli-cation of SCR priming VLP boosting as a novel vaccination strategy against HIV-1. Curr. HIV Res. 2011,9(3),140-147. http:\/\/dx.doi.org\/10.2174\/157016211795945223 PMID: 21443517","journal-title":"Curr.HIV Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","volume":"11(493)","author":"Milani,M.","year":"2019","unstructured":"Milani,M.; Annoni,A.; Moa-lli,F.; Liu,T.; Cesana,D.; Calabria,A.; Bartolaccini,S.; Biffi,M.; Russo,F.; Visigalli,I.; Raimondi,A.; Patar-royo-White,S.; Drager,D.; Cristofori,P.; Ayuso,E.; Montini,E.; Pe-ters,R.; Iannacone,M.; Cantore,A.; Naldini, L. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci. Transl. Med. 2019,11(493),eaav7325. http:\/\/dx.doi.org\/10.1126\/scitranslmed.aav7325 PMID: 31118293","journal-title":"Sci.Transl.Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41434-018-0056-1","volume":"26(3-4)","author":"Karda,R.","year":"2019","unstructured":"Karda,R.; Counsell, J.R.; Karbowniczek,K.; Caproni, L.J.; Tite, J.P.; Waddington, S.N. Production of lentiviral vectors using novel, enzy-matically produced, linear DNA. Gene Ther. 2019,26(3-4),86-92. http:\/\/dx.doi.org\/10.1038\/s41434-018-0056-1 PMID: 30643205","journal-title":"Gene Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1128\/JVI.01284-09","volume":"83(21)","author":"Beignon, A.S.","year":"2009","unstructured":"Beignon, A.S.; Mollier,K.; Liard,C.; Coutant,F.; Munier,S.; Rivi\u00e8re,J.; Souque,P.; Charneau, P. Lentiviral vector-based prime\/boost vac-cination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques, J. Virol. 2009,83(21),10963-10974. http:\/\/dx.doi.org\/10.1128\/JVI.01284-09 PMID: 19706700","journal-title":"Virol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1099\/vir.0.81706-0","volume":"87(Pt 6)","author":"Buffa,V.","year":"2006","unstructured":"Buffa,V.; Negri, D.R.; Leone,P.; Bona,R.; Borghi,M.; Bacigalupo,I.; Carlei,D.; Sgadari,C.; Ensoli,B.; Cara, A. A single administration of lentiviral vectors expressing either full-length Human Immunodefi-ciency Virus 1 (HIV-1) (HXB2)  Rev\/Env or codon-optimized HIV-1(JR-FL)  gp120 generates durable immune responses in mice, J. Gen. Virol. 2006,87(Pt 6),1625-1634. http:\/\/dx.doi.org\/10.1099\/vir.0.81706-0 PMID: 16690927","journal-title":"Gen.Virol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.vaccine.2009.10.089","volume":"28(8)","author":"Lemiale,F.","year":"2010","unstructured":"Lemiale,F.; Asefa,B.; Ye,D.; Chen,C.; Korokhov,N.; Humeau, L. An HIV-based lentiviral vector as HIV vaccine candidate: immuno-genic characterization. Vaccine. 2010,28(8),1952-1961. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2009.10.089 PMID: 20188251","journal-title":"Vaccine"},{"key":"ref=43","first-page":"243","volume":"7","author":"Norton, T.D.","year":"2016","unstructured":"Norton, T.D.; Miller, E.A. Recent advances in lentiviral vaccines for HIV-1 infection. Front. Immunol. 2016,7,243-243 PMID: 27446074","journal-title":"Front..Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2174\/1570162X17666190102151717","volume":"16(5)","author":"Larijani, M.S.","year":"2018","unstructured":"Larijani, M.S.; Sadat, S.M.; Bolhassani,A.; Pouriayevali, M.H.; Bah-ramali,G.; Ramezani, A. In silico design and immunologic evaluation of HIV-1 p24-Nef fusion protein to approach a therapeutic vaccine candidate. Curr. HIV Res. 2018,16(5),322-337. http:\/\/dx.doi.org\/10.2174\/1570162X17666190102151717 PMID: 30605062","journal-title":"Curr.HIV Res"},{"key":"ref=45","author":"Sambrook,J.R. .D","unstructured":"Sambrook.; J.R.D. Molecular cloning 3 rd edition; CSHL press: New York. 2001,200.","journal-title":"2001,200"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1473-3099(11) 70098-6","volume":"11(7)","author":"Gray, G.E.","year":"2011","unstructured":"Gray, G.E.; Allen,M.; Moodie,Z.; Churchyard,G.; Bekker, L.G.; Nchabeleng,M.; Mlisana,K.; Metch,B.; de Bruyn,G.; Latka, M.H.; Roux,S.; Mathebula,M.; Naicker,N.; Ducar,C.; Carter, D.K.; Puren,A.; Eaton,N.; McElrath, M.J.; Robertson,M.; Corey,L.; Kublin, J.G. HVTN 503\/Phamb ili study team. Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 2011,11(7),507-515. http:\/\/dx.doi.org\/10.1016\/S1473-3099(11) 70098-6 PMID: 21570355","journal-title":"Lancet Infect.Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(08) 61591-3","volume":"372(9653)","author":"Buchbinder, S.P.","year":"2008","unstructured":"Buchbinder, S.P.; Mehrotra, D.V.; Duerr,A.; Fitzgerald, D.W.; Mogg,R.; Li,D.; Gilbert, P.B.; Lama, J.R.; Marmor,M.; Del Rio,C.; McElrath, M.J.; Casimiro, D.R.; Gottesdiener, K.M.; Chodakewitz, J.A.; Corey,L.; Robertson, M.N. Step study protocol team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008,372(9653),1881-1893. http:\/\/dx.doi.org\/10.1016\/S0140-6736(08) 61591-3 PMID: 19012954","journal-title":"Lancet"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361(23)","author":"Rerks-Ngarm,S.","year":"2009","unstructured":"Rerks-Ngarm,S.; Pitisuttithum,P.; Nitayaphan,S.; Kaewkungwal,J.; Chiu,J.; Paris,R.; Premsri,N.; Namwat,C.; de Souza,M.; Adams,E.; Benenson,M.; Gurunathan,S.; Tartaglia,J.; McNeil, J.G.; Francis, D.P.; Stablein,D.; Birx, D.L.; Chunsu-ttiwat,S.; Khamboonruang,C.; Thongcharoen,P.; Robb, M.L.; Michael, N.L.; Kunasol,P.; Kim, J.H. MOPH-TAVEG Investigators. Vaccination with ALVAC and AID-SVAX to prevent HIV-1 infection in Thailand, N. Engl, J. Med. 2009,361(23),2209-2220. http:\/\/dx.doi.org\/10.1056\/NEJMoa0908492 PMID: 19843557","journal-title":"N.Engl, J.Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12977-015-0151-y","volume":"12","author":"Ensoli,F.","year":"2015","unstructured":"Ensoli,F.; Cafaro,A.; Casabianca,A.; Tripiciano,A.; Bellino,S.; Longo,O.; Francav-illa,V.; Picconi,O.; Sgadari,C.; Moretti,S.; Cos-sut, M.R.; Arancio,A.; Orlandi,C.; Sernicola,L.; Maggiorella, M.T.; Paniccia,G.; Mussini,C.; Lazzarin,A.; Sighinolfi,L.; Palamara,G.; Gori,A.; Angarano,G.; Di Pietro,M.; Galli,M.; Mercurio, V.S.; Castelli,F.; Di Perri,G.; Monini,P.; Magnani,M.; Garaci,E.; Ensoli, B. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant bl ood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology. 2015,12,33. http:\/\/dx.doi.org\/10.1186\/s12977-015-0151-y PMID: 25924841","journal-title":"Retrovirology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1089\/aid.2016.0168","volume":"33(8)","author":"Tarosso, L.F.","year":"2017","unstructured":"Tarosso, L.F.; Vieira, V.A.; Sauer, M.M.; Tomiyama, H.I.; Kalil,J.; Kallas, E.G. Conserved HIV-1 gag p24 epitopes elicit cellular immune responses that impact disease outcome. AIDS Res. Hum. Retroviruses. 2017,33(8),832-842. http:\/\/dx.doi.org\/10.1089\/aid.2016.0168 PMID: 28594230","journal-title":"AIDS Res.Hum.Retroviruses"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00002030-199802000-00007","volume":"12(2)","author":"Kelleher, A.D.","year":"1998","unstructured":"Kelleher, A.D.; Roggensack,M.; Jaram-illo, A.B.; Smith, D.E.; Walker,A.; Gow,I.; McMurchie,M.; Harris,J.; Patou,G.; Cooper, D.A. Community HIV research network investigators. Safety and im-munogenicity of a candidate therapeutic vaccine, p24 virus-like parti-cle, combined with zidovudine, in asymptomatic subjects. AIDS. 1998,12(2),175-182. http:\/\/dx.doi.org\/10.1097\/00002030-199802000-00007 PMID: 9468366","journal-title":"AIDS"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e0125954","DOI":"10.1371\/journal.pone.0125954","volume":"10(5)","author":"Omosa-Manyonyi,G.","year":"2015","unstructured":"Omosa-Manyonyi,G.; Mpendo,J.; Ruzagira,E.; Kilembe,W.; Chomba,E.; Roman,F.; Bourguignon,P.; Koutsoukos,M.; Collard,A.; Voss,G.; Laufer,D.; Stevens,G.; Hayes,P.; Clark,L.; Cormier,E.; Dally,L.; Barin,B.; Ackland,J.; Syvertsen,K.; Zachariah,D.; Anas,K.; Sayeed,E.; Lombardo,A.; Gilmour,J.; Cox,J.; Fast,P.; Priddy, F. A Phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein and adenovirus 35 Gag-RT-Int-Nef vaccine in healthy HIV-uninfected african adults. PLoS One. 2015,10(5),e0125954. http:\/\/dx.doi.org\/10.1371\/journal.pone.0125954 PMID: 25961283","journal-title":"PLoS One"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4149\/av_2010_02_131","volume":"54(2)","author":"Mahdavi,M.","year":"2010","unstructured":"Mahdavi,M.; Ebtekar,M.; Azadmanesh,K.; Khorramkhorshid, H.R.; Rahbarizadeh,F.; Yazdi, M.H.; Zabihollahi,R.; Abolhassani,M.; Has-san, Z.M. HIV-1 Gag p24-Nef fusion peptide induces cellular and hu-moral immune response in a mouse model. Acta Virol. 2010,54(2),131-136. http:\/\/dx.doi.org\/10.4149\/av_2010_02_131 PMID: 20545443","journal-title":"Acta Virol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1467-7652.2011.00609.x","volume":"9(6)","author":"Gonzalez-Rabade,N.","year":"2011","unstructured":"Gonzalez-Rabade,N.; McGowan, E.G.; Zhou,F.; McCabe, M.S.; Bock,R.; Dix, P.J.; Gray, J.C.; Ma, J.K. Immunogenicity of chloro-plast-derived HIV-1 p24 and a p24-Nef fusion protein following sub-cutaneous and oral administration in mice. Plant Biotechnol, J. 2011,9(6),629-638. http:\/\/dx.doi.org\/10.1111\/j.1467-7652.2011.00609.x PMID: 21443546","journal-title":"Plant Biotechnol, J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0958-1669(98) 80029-3","volume":"9(5)","author":"Naldini,L","year":"1998","unstructured":"Naldini.; L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 1998,9(5),457-463. http:\/\/dx.doi.org\/10.1016\/S0958-1669(98) 80029-3 PMID: 9821272","journal-title":"Curr.Opin.Biotechnol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.omtn.2019.10.024","volume":"18","author":"Delviks-Frankenberry, K.A.","year":"2019","unstructured":"Delviks-Frankenberry, K.A.; Acke-rman,D.; Timberlake, N.D.; Ham-scher,M.; Nikolaitchik, O.A.; Hu, W-S.; Torbett, B.E.; Pathak, V.K. Development of lentiviral vectors for HIV-1 gene therapy with Vif-resistant APOBEC3G. Mol. Ther. Nucleic Acids. 2019,18,1023-1038. http:\/\/dx.doi.org\/10.1016\/j.omtn.2019.10.024 PMID: 31778955","journal-title":"Mol.Ther.Nucleic Acids"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e00415","DOI":"10.1128\/mSphere.00415-17","volume":"2(6)","author":"Alayo, Q.A.","year":"2017","unstructured":"Alayo, Q.A.; Provine, N.M.; Penaloza-MacMaster, P. Novel concepts for HIV vaccine vector design. MSphere. 2017,2(6),e00415-e00417. http:\/\/dx.doi.org\/10.1128\/mSphere.00415-17 PMID: 29242831","journal-title":"MSphere"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"20382","DOI":"10.1073\/pnas.0911742106","volume":"106(48)","author":"Dai,B.","year":"2009","unstructured":"Dai,B.; Yang,L.; Yang,H.; Hu,B.; Baltimore,D.; Wang, P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine di-rected to dendritic cells. Proc. Natl. Acad. Sci. USA. 2009,106(48),20382-20387. http:\/\/dx.doi.org\/10.1073\/pnas.0911742106 PMID: 19918062","journal-title":"Proc.Natl.Acad.Sci.USA"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ymthe.2019.03.008","volume":"27(5)","author":"Norton, T.D.","year":"2019","unstructured":"Norton, T.D.; Zhen,A.; Tada,T.; Kim,J.; Kitchen,S.; Landau, N.R. Lentiviral vector-based dendritic cell vaccine suppresses HIV replica-tion in humanized mice. Mol. Ther. 2019,27(5),960-973. http:\/\/dx.doi.org\/10.1016\/j.ymthe.2019.03.008 PMID: 30962161","journal-title":"Mol.Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3390\/vaccines6010010","volume":"6(1)","author":"Andersson, A.C.","year":"2018","unstructured":"Andersson, A.C.; Schwerdtfeger,M.; Holst, P.J. Virus-like-vaccines against HIV. Vaccines (Basel). 2018,6(1),E10. http:\/\/dx.doi.org\/10.3390\/vaccines6010010 PMID: 29439476","journal-title":"Vaccines (Basel)"},{"key":"ref=61","author":"Vzorov, A.N.","unstructured":"Vzorov, A.N.; Compans, R.W. VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties. Mol. Biol. (Mosk.),2016,50(3),406-415. PMID: 27414779","journal-title":"Mol.Biol.(Mosk..)"},{"key":"ref=62","first-page":"434","volume":"15(6)","author":"Tohidi,F.","year":"2017","unstructured":"Tohidi,F.; Sadat, S.M.; Bolhassani,A.; Yaghobi, R. Construction and production of HIV-VLP harboring MPER-V3 for potential vaccine study. Curr. HIV Res. 2017,15(6),434-439. PMID: 29046160","journal-title":"Curr.HIV Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1007\/s00253-018-8930-8","volume":"102(10)","author":"Fuenmayor,J.","year":"2018","unstructured":"Fuenmayor,J.; Cervera,L.; Rigau,C.; G\u00f2dia, F. Enhancement of HIV-1 VLP production using gene inhib ition strategies. Appl. Micro-biol. Biotechnol. 2018,102(10),4477-4487. http:\/\/dx.doi.org\/10.1007\/s00253-018-8930-8 PMID: 29574615","journal-title":"Appl.Micro-biol.Biotechnol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e0203635","DOI":"10.1371\/journal.pone.0203635","volume":"13(8)","author":"Calazans,A.","year":"2018","unstructured":"Calazans,A.; Boggiano,C.; Linds-ay, R. Retraction: A DNA inducing VLP vaccine designed for HIV and tested in mice. PLoS One. 2018,13(8),e0203635. http:\/\/dx.doi.org\/10.1371\/journal.pone.0203635 PMID: 30170323","journal-title":"PLoS One"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1570162X17666190306124218","volume":"17(1)","author":"Tohidi,F.","year":"2019","unstructured":"Tohidi,F.; Sadat, S.M.; Bolhassani,A.; Yaghobi,R.; Larijani, M.S. Induction of a robust humoral response using HIV-1 VLPMPER-V3as a novel candidate vaccine in BALB\/c mice. Curr. HIV Res. 2019,17(1),33-41. http:\/\/dx.doi.org\/10.2174\/1570162X17666190306124218 PMID: 30843489","journal-title":"Curr.HIV Res"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T14:55:59Z","timestamp":1605020159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180294\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,7,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201817666200317121728","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}